RS61752B1 - 7-supstituisana jedinjenja sulfonimidoil purinona za lečenje i profilaksu virusne infekcije - Google Patents

7-supstituisana jedinjenja sulfonimidoil purinona za lečenje i profilaksu virusne infekcije

Info

Publication number
RS61752B1
RS61752B1 RS20210489A RSP20210489A RS61752B1 RS 61752 B1 RS61752 B1 RS 61752B1 RS 20210489 A RS20210489 A RS 20210489A RS P20210489 A RSP20210489 A RS P20210489A RS 61752 B1 RS61752 B1 RS 61752B1
Authority
RS
Serbia
Prior art keywords
prophylaxis
treatment
virus infection
substituted
compounds
Prior art date
Application number
RS20210489A
Other languages
English (en)
Inventor
Lu Gao
Chungen Liang
Hongying Yun
Xiufang Zheng
Jianping Wang
Kun Miao
Bo Zhang
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of RS61752B1 publication Critical patent/RS61752B1/sr

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D473/00Heterocyclic compounds containing purine ring systems
    • C07D473/02Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
    • C07D473/24Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 one nitrogen and one sulfur atom
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52Purines, e.g. adenine
    • A61K31/522Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/20Antivirals for DNA viruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/04Immunostimulants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
RS20210489A 2016-08-29 2017-08-28 7-supstituisana jedinjenja sulfonimidoil purinona za lečenje i profilaksu virusne infekcije RS61752B1 (sr)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
CN2016097140 2016-08-29
CN2017092653 2017-07-12
EP17758527.0A EP3504210B1 (en) 2016-08-29 2017-08-28 7-substituted sulfonimidoylpurinone compounds for the treatment and prophylaxis of virus infection
PCT/EP2017/071514 WO2018041763A1 (en) 2016-08-29 2017-08-28 7-substituted sulfonimidoylpurinone compounds for the treatment and prophylaxis of virus infection

Publications (1)

Publication Number Publication Date
RS61752B1 true RS61752B1 (sr) 2021-05-31

Family

ID=59738346

Family Applications (1)

Application Number Title Priority Date Filing Date
RS20210489A RS61752B1 (sr) 2016-08-29 2017-08-28 7-supstituisana jedinjenja sulfonimidoil purinona za lečenje i profilaksu virusne infekcije

Country Status (31)

Country Link
US (3) US10233184B2 (sr)
EP (2) EP3865482A1 (sr)
JP (2) JP7013467B2 (sr)
KR (2) KR20220147702A (sr)
CN (1) CN109641904B (sr)
AU (3) AU2017320742B2 (sr)
BR (1) BR112019003519A2 (sr)
CA (1) CA3034148A1 (sr)
CL (1) CL2019000512A1 (sr)
CO (1) CO2019000932A2 (sr)
CR (1) CR20190087A (sr)
DK (1) DK3504210T3 (sr)
ES (1) ES2867849T3 (sr)
HR (1) HRP20210621T1 (sr)
HU (1) HUE053944T2 (sr)
IL (3) IL293475A (sr)
MA (1) MA46038B1 (sr)
MX (2) MX2019002129A (sr)
MY (1) MY197408A (sr)
NZ (1) NZ750604A (sr)
PE (1) PE20190476A1 (sr)
PH (1) PH12019500432A1 (sr)
PL (1) PL3504210T3 (sr)
PT (1) PT3504210T (sr)
RS (1) RS61752B1 (sr)
RU (1) RU2751349C2 (sr)
SG (2) SG10202010520SA (sr)
SI (1) SI3504210T1 (sr)
TW (1) TWI671300B (sr)
UA (1) UA124270C2 (sr)
WO (1) WO2018041763A1 (sr)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2982704C (en) * 2015-05-08 2023-10-24 F. Hoffmann-La Roche Ag Sulfonimidoylpurinone compounds and derivatives for the treatment and prophylaxis of virus infection
CR20190087A (es) * 2016-08-29 2019-04-30 Hoffmann La Roche Nuevos compuestos sulfonimidoilpurinova 7-sustituídos y derivados para el tratamiento y la profilaxis de la infección vírica
EP3970750A1 (en) * 2016-09-13 2022-03-23 F. Hoffmann-La Roche AG Combined treatment with a tlr7 agonist and an hbv capsid assembly inhibitor
CN111699187A (zh) 2018-02-12 2020-09-22 豪夫迈·罗氏有限公司 用于治疗和预防病毒感染的新的砜化合物和衍生物
KR20200128414A (ko) * 2018-02-28 2020-11-12 에프. 호프만-라 로슈 아게 간암의 치료 및 예방을 위한 7-치환된 설폰이미도일퓨린온 화합물 및 유도체
US20200113912A1 (en) 2018-09-12 2020-04-16 Silverback Therapeutics, Inc. Methods and Compositions for the Treatment of Disease with Immune Stimulatory Conjugates
WO2020162705A1 (ko) 2019-02-08 2020-08-13 성균관대학교산학협력단 톨-유사 수용체 7 또는 8 작용자와 콜레스테롤의 결합체 및 그 용도
WO2021067644A1 (en) 2019-10-01 2021-04-08 Silverback Therapeutics, Inc. Combination therapy with immune stimulatory conjugates
JP2023514727A (ja) 2020-02-21 2023-04-07 シルバーバック セラピューティックス インコーポレイテッド ネクチン-4抗体コンジュゲートおよびその使用
WO2021177679A1 (ko) 2020-03-02 2021-09-10 성균관대학교산학협력단 병원균 외벽 성분 기반 생병원체 모방 나노 입자 및 그 제조 방법
CA3183993A1 (en) 2020-07-01 2022-01-06 Peter R. Baum Anti-asgr1 antibody conjugates and uses thereof
EP4194006A1 (en) 2020-08-04 2023-06-14 Progeneer Inc. Mrna vaccine comprising adjuvant capable of kinetic control
US20230277525A1 (en) 2020-08-04 2023-09-07 Progeneer Inc Conjugate of functional drug and toll-like receptor 7 or 8 agonist of which active site is temporarily inactivated and use thereof
WO2022031011A1 (ko) 2020-08-04 2022-02-10 성균관대학교산학협력단 동력학적으로 작용하는 아주번트 앙상블
WO2022063278A1 (zh) * 2020-09-27 2022-03-31 上海维申医药有限公司 大环tlr7激动剂、其制备方法、药物组合物及其用途

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0141927B1 (en) * 1983-08-18 1991-10-30 Beecham Group Plc Antiviral guanine derivatives
ES2232871T3 (es) 1996-07-03 2005-06-01 Sumitomo Pharmaceuticals Company, Limited Nuevos derivados de purina.
AUPO912997A0 (en) * 1997-09-11 1997-10-02 Commonwealth Scientific And Industrial Research Organisation Antiviral agents
KR100613634B1 (ko) * 1997-11-28 2006-08-18 다이닛본 스미토모 세이야꾸 가부시끼가이샤 신규한 복소환 화합물
JPH11180981A (ja) * 1997-12-19 1999-07-06 Sumitomo Pharmaceut Co Ltd 複素環誘導体
TW572758B (en) 1997-12-22 2004-01-21 Sumitomo Pharma Type 2 helper T cell-selective immune response inhibitors comprising purine derivatives
JP4189048B2 (ja) * 1997-12-26 2008-12-03 大日本住友製薬株式会社 複素環化合物
DE60329375D1 (en) * 2002-03-15 2009-11-05 Univ Wayne State Neue 2-amino-9-((2-hydroxymethyl)cyclopropylidenmethyl)-purine als antivirale mittel
ES2387388T3 (es) * 2002-09-27 2012-09-21 Dainippon Sumitomo Pharma Co., Ltd. Compuesto de adenina y uso del mismo
MX2007013780A (es) 2005-05-04 2008-02-05 Pfizer Ltd Derivados 2 amido-6-amino-8-oxo purina como moduladores del receptor como tipo peaje (toll) para el tratamiento del cancer y las infecciones virales tal como la hepatitis c.
DE102006053049A1 (de) 2006-11-10 2008-05-15 Daimler Ag Staufach mit einer Abdeckeinrichtung
PT2170888E (pt) * 2007-06-29 2015-08-21 Gilead Sciences Inc Purina derivados e sua utilização como moduladores de recetor de tipo toll 7
CN101239980B (zh) 2008-02-18 2011-06-22 靳广毅 免疫受体调节剂偶联体前体和偶联体及其应用
CN102272134B (zh) * 2008-12-09 2013-10-16 吉里德科学公司 Toll样受体调节剂
WO2011049825A1 (en) * 2009-10-22 2011-04-28 Gilead Sciences, Inc. Derivatives of purine or deazapurine useful for the treatment of (inter alia) viral infections
US20110150836A1 (en) 2009-12-22 2011-06-23 Gilead Sciences, Inc. Methods of treating hbv and hcv infection
US8501724B1 (en) * 2012-01-31 2013-08-06 Pharmacyclics, Inc. Purinone compounds as kinase inhibitors
LT3190113T (lt) 2014-08-15 2021-08-25 Chia Tai Tianqing Pharmaceutical Group Co., Ltd. Pirolopirimidino junginiai, naudotini kaip tlr7 agonistai
CA2982704C (en) * 2015-05-08 2023-10-24 F. Hoffmann-La Roche Ag Sulfonimidoylpurinone compounds and derivatives for the treatment and prophylaxis of virus infection
CR20190087A (es) * 2016-08-29 2019-04-30 Hoffmann La Roche Nuevos compuestos sulfonimidoilpurinova 7-sustituídos y derivados para el tratamiento y la profilaxis de la infección vírica

Also Published As

Publication number Publication date
CL2019000512A1 (es) 2019-07-12
JP7013467B2 (ja) 2022-01-31
EP3865482A1 (en) 2021-08-18
KR20190039829A (ko) 2019-04-15
AU2022204697A1 (en) 2022-07-21
US20180072730A1 (en) 2018-03-15
KR102459155B1 (ko) 2022-10-28
SG11201901633WA (en) 2019-03-28
CO2019000932A2 (es) 2019-02-08
PE20190476A1 (es) 2019-04-04
EP3504210A1 (en) 2019-07-03
RU2019107957A (ru) 2020-09-29
SG10202010520SA (en) 2020-11-27
HUE053944T2 (hu) 2021-08-30
JP2022050632A (ja) 2022-03-30
SI3504210T1 (sl) 2021-08-31
UA124270C2 (uk) 2021-08-18
PT3504210T (pt) 2021-04-19
CN109641904B (zh) 2022-01-28
US10752630B2 (en) 2020-08-25
TWI671300B (zh) 2019-09-11
AU2017320742A1 (en) 2019-02-28
ES2867849T3 (es) 2021-10-21
WO2018041763A1 (en) 2018-03-08
JP2019526633A (ja) 2019-09-19
US20190256515A1 (en) 2019-08-22
AU2021204303B2 (en) 2022-05-12
CR20190087A (es) 2019-04-30
IL284255A (en) 2021-07-29
AU2017320742B2 (en) 2021-08-05
MA46038A (fr) 2019-07-03
EP3504210B1 (en) 2021-02-24
MX2021006902A (es) 2021-07-07
US20200385387A1 (en) 2020-12-10
BR112019003519A2 (pt) 2019-05-21
US10233184B2 (en) 2019-03-19
HRP20210621T1 (hr) 2021-05-28
RU2751349C2 (ru) 2021-07-13
DK3504210T3 (da) 2021-04-26
MA46038B1 (fr) 2021-05-31
CA3034148A1 (en) 2018-03-08
NZ750604A (en) 2024-02-23
RU2019107957A3 (sr) 2020-12-18
IL284255B (en) 2022-07-01
PL3504210T3 (pl) 2021-07-05
KR20220147702A (ko) 2022-11-03
TW201819382A (zh) 2018-06-01
AU2021204303A1 (en) 2021-07-22
CN109641904A (zh) 2019-04-16
IL264710B (en) 2021-07-29
PH12019500432A1 (en) 2019-10-21
IL293475A (en) 2022-08-01
JP7214900B2 (ja) 2023-01-30
MY197408A (en) 2023-06-16
MX2019002129A (es) 2019-06-20

Similar Documents

Publication Publication Date Title
IL284255A (en) 7-substituted sulfonimidylpurinone compounds for the treatment and prevention of viral infection
HK1251554A1 (zh) 用於治療和預防病毒感染的新的取代的氨基噻唑並嘧啶二酮
HK1248711A1 (zh) 用於治療和預防病毒感染的新的取代的氨基噻唑並嘧啶二酮
HRP20190352T1 (hr) Novi 6-kondenzirani heteroarildihidropirimidini za liječenje i profilaksu infekcije virusom hepatitisa b
HUS2200053I1 (hu) HIV vírusfertõzés megelõzõ vagy terápiás kezelésére alkalmas terápiás vegyületek
HK1251221A1 (zh) 用於治療和預防乙型肝炎病毒感染的新的三環4-吡啶酮-3-甲酸衍生物
HK1251220A1 (zh) 用於治療和預防乙型肝炎病毒感染的新的四環4-氧代-吡啶-3-甲酸衍生物
HK1223931A1 (zh) 用於治療和預防乙型肝炎病毒感染的新型二氫喹嗪酮類化合物
IL263972A (en) Dihydropyranopyrimidines for the treatment of viral infections
IL280769A (en) New sulfonimidylpurinone compounds and their history for the treatment and prevention of virus infection
HK1252343A1 (zh) 用於治療病毒感染的組合物和方法
ZA201900770B (en) 7-substituted sulfonimidoylpurinone compounds for the treatment and prophylaxis of virus infection
LT3504210T (lt) Nauji 7 padėtyje pakeisti sulfonimidoilpurinono junginiai, skirti viruso sukeliamos infekcijos gydymui ir profilaktikai
ZA201604784B (en) Novel 6-fused heteroaryldihydropyrimidines for the treatment and prophylaxis of hepatitis b virus infection